In the fight against the deadliest drug crisis in American history, one of the most promising weapons is a converted bus parked on a main road in Woonsocket, Rhode Island. A new study published in Addiction Science & Clinical Practice offers the most detailed look yet at how a mobile health unit delivering medications for opioid use disorder has functioned on the ground—documenting both its life-saving reach and the stubborn structural obstacles that threaten its survival.

The research, led by Augustine Kang of Boston Children’s Hospital and Amelia Bailey of the Brown University School of Public Health, together with colleagues at CODAC Behavioral Healthcare and the University of Massachusetts Chan Medical School, examined the implementation and impact of a mobile unit launched in July 2022 by CODAC, Rhode Island’s largest provider of opioid treatment services. The unit operates in two capacities: as a fully licensed opioid treatment program that prescribes and dispenses medications six days a week in Woonsocket—a city with one of the highest per capita overdose rates in the state—and as a community outreach service providing harm reduction supplies, counseling, and linkages to care in under-resourced areas.

To understand how the unit works in practice, the research team conducted semi-structured qualitative interviews with 15 stakeholders between August and November 2024. Participants included mobile unit staff and clinicians, staff from CODAC’s brick-and-mortar clinics, organizational leadership, community partners, and a representative of the State Opioid Treatment Authority. Interviews, which averaged 54 minutes, were analyzed using a template thematic approach organized around the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, supplemented by principles from the Health Equity Implementation Framework. The researchers reached thematic saturation after 12 interviews and used NVivo software to code and organize the data.

The picture that emerged is one of an intervention that is simultaneously indispensable and precarious. Stakeholders overwhelmingly endorsed the mobile unit as a critical tool for reaching people whom the traditional treatment system has failed: people experiencing homelessness, economic instability, and the transportation barriers that make daily visits to a fixed clinic nearly impossible. Because federal regulations require in-person contact to initiate methadone treatment, participants explained, people who are unhoused or transient often cannot access care at all. The mobile unit dissolves that barrier by bringing dosing, assessment, and intake directly into the neighborhoods where patients live.

The unit’s value extends well beyond medication itself. Participants described how the unit functions as a comprehensive health hub—offering blood pressure checks, wound care, harm reduction supplies such as clean needle and wound kits, and referrals to primary care for unmanaged chronic conditions like hypertension and diabetes. Staff noted that many patients arrive with years of neglected medical needs, and the mobile unit serves as a re-entry point into the broader health system. This integrated model, the authors note, aligns with research showing that combining medications for opioid use disorder with primary care improves retention in treatment and overall health outcomes.

Perhaps the most striking finding concerns the quality of relationships the unit fosters. Unlike conventional clinics, where patients described a culture of arriving, dosing, and leaving, the mobile unit’s compact environment allows staff to know patients by name and build therapeutic rapport more quickly. Participants credited this familiarity with keeping people engaged in care even during periods of active substance use, describing a welcoming, nonjudgmental “family-oriented environment.” Practical incentives also mattered: early monetary incentives in the form of small gift cards drew patients in, but over time, staff reported, external motivation gave way to intrinsic motivation. The ability to earn take-home doses of methadone emerged as one of the strongest retention tools, giving patients a tangible goal and a growing sense of autonomy.

Stakeholders also described how the medications themselves transform lives. Participants with years of clinical experience described patients regaining “breathing room”—freedom from the daily cycle of withdrawal and drug-seeking that allowed them to rebuild families, secure employment, and escape legal entanglements. Several recounted patients bringing parents, children, and partners into treatment, breaking cycles of generational addiction. One staff member of 14 years described watching people go from rock bottom to full-time jobs and stable family lives.

Yet the study is equally candid about the forces working against the unit. Staffing shortages loomed over nearly every conversation: the unit is not fully staffed, and counseling and case management services are provided by staff rotated in from Providence rather than a dedicated mobile team. Low insurance reimbursement rates and the precarious nature of grant funding left participants worried about long-term sustainability. The physical constraints of the vehicle itself—only one enclosed office space for private conversations, with counseling elsewhere conducted behind dividers and sound machines—require a specific kind of professional who thrives on outreach work. Weather posed its own hazards: after patients were found waiting in freezing snow, the unit changed its policy to provide take-home doses whenever snow was forecast.

External resistance proved equally formidable. Stakeholders described political opposition from municipal officials who attempted to use zoning ordinances to shut down services in one community, requiring legal intervention to resolve. Law enforcement activity near treatment sites—such as traffic stops targeting patients arriving for care—forced some patients to weigh the risk of arrest against their need for medication. Remarkably, however, the study also documents a counter-trend: through proactive engagement and education, staff built relationships with police departments, and in some cases officers began referring individuals to the unit instead of arresting them. Over time, sustained operation also softened community stigma, as residents observed that the unit did not produce the negative consequences they had feared.

The authors are careful to note a key limitation: no patients were interviewed directly, so all findings about patient experiences reflect staff and stakeholder perceptions rather than patients’ own voices. Even so, the implications are clear. The number of federally approved methadone mobile units in the United States has grown from just 8 in 2022 to 64 by early 2025, following the reversal of a Drug Enforcement Administration moratorium that had blocked expansion since 2007. Yet a recent scoping review cited in the study found that such units remain under-utilized, suggesting both unmet need and unrealized potential.

The stakeholders in this study offered a roadmap for realizing that potential: better marketing and outreach, including social media presence; large-scale de-stigmatization campaigns framed around the simple logic that addiction should be treated like any other medical condition; expanded staffing, including additional nurses and providers; improved language access for non-English speakers; stronger partnerships with housing services and food pantries; and, above all, stable long-term funding. Some participants also envisioned expanded services such as community drug-checking for polysubstance users—a ground-level harm reduction tool suited to the modern, fentanyl-saturated drug supply.

What the study ultimately documents is a model of care that works—not in the abstract, but in the specific, textured reality of snowy parking lots, gift card incentives, police negotiations, and patients who show up even at their lowest points. The unit’s flexibility is itself a structural advantage: unlike a fixed clinic, a bus can move if a neighborhood objects. As one participant put it, “the bus makes it a little bit less scary.” Whether these lifelines on wheels become a permanent fixture of the American addiction treatment landscape will depend less on clinical evidence—which increasingly supports them—than on the funding streams, policies, and political will required to keep the engines running.

The opioid crisis has precipitated robust public health responses designed to curtail inappropriate opioid use, aiming to mitigate risks such as opioid use disorder and overdose fatalities. However, policies implemented to address this national emergency may unintentionally hamper access to necessary analgesic therapies in vulnerable populations, particularly among cancer patients. Pain management in oncology remains a critical component of patient care, and any reduction in opioid availability carries the risk of suboptimal symptom control and decreased quality of life.

To parse out prescribing patterns in this complex clinical scenario, investigators utilized comprehensive healthcare data for over 10,000 adult patients, focusing on those without prior opioid prescriptions and newly diagnosed with cancer between 2016 and 2020. They operationally defined “new opioid prescriptions” as those issued within the first six months following cancer diagnosis. Additionally, “additional prescriptions” encompassed opioid orders issued both within the initial six months and between months seven to nine post-diagnosis, providing a longitudinal perspective on opioid use as patients progressed through various stages of cancer treatment.

Their findings documented a discernible decline in new opioid prescribing, decreasing from 71.1% in 2016 to 64.6% in 2020. Similarly, the proportion of patients receiving additional opioid prescriptions dropped modestly from 27.2% to 24.2% over the same period. Among the subset of patients undergoing cancer-directed surgery, initial opioid prescribing decreased more markedly, from a striking 96.0% to 88.6%, though additional opioid prescribing remained relatively stable at around 13%. These data points suggest a cautious yet judicious approach by clinicians in the immediate postoperative period and subsequent recovery phases.

The analysis further stratified patients with metastatic cancer according to their self-reported pain status, revealing critical distinctions in prescribing behavior. For metastatic patients reporting pain, new opioid prescribing remained constant at approximately 56%, indicating sustained attention to analgesia in symptomatic individuals. Conversely, new opioid prescribing steeply declined among metastatic patients who reported no pain, decreasing from 61.6% to 36.1%, reflecting an acute sensitivity to clinical context and patient-reported symptoms when making analgesic decisions.

This study’s lead author, Dr. Laura Van Metre Baum, MD, MPH, formerly affiliated with the Yale School of Medicine and currently at Dana-Farber Cancer Institute, emphasized the delicate equilibrium clinicians must achieve. “The treatment of cancer-related pain amid the ongoing opioid epidemic is complicated,” Dr. Van Metre Baum remarked. The findings provide reassurance that observed declines in opioid prescribing largely mirror nuanced clinical judgment rather than indiscriminate reductions. Nonetheless, she highlighted continuing challenges in guaranteeing consistent and adequate pain control for all cancer patients, signaling an urgent need for refined strategies and guidelines.

From a clinical pharmacology perspective, this research underscores the relevance of individualized pain assessment and the integration of patient-reported outcomes in guiding opioid management. The differential prescribing trends based on pain reporting in metastatic disease highlight a paradigm where therapeutic decisions are increasingly tailored to objective and subjective illness parameters. Such an approach aligns with contemporary frameworks emphasizing precision medicine and risk-benefit optimization in analgesic stewardship.

Moreover, the decline in opioid prescribing also invites deeper exploration of alternative analgesic modalities and multimodal pain management strategies that may be gaining traction as adjuncts or substitutes in oncology care. Non-opioid pharmacotherapies, interventional techniques, and integrative practices may be contributing to these evolving trends, although the study’s scope primarily centers on opioid utilization metrics rather than the broader analgesic armamentarium.

The potential consequences of these shifts resonate beyond pharmacologic quantities; under-treatment of cancer-related pain can precipitate profound detriments in functional status, psychological well-being, and treatment adherence. Maintaining access to effective pain relief while minimizing risks of opioid misuse remains a formidable clinical and societal challenge, demanding ongoing surveillance and adaptive policy frameworks responsive to emerging evidence.

This research also spotlights the broader implications of health policy intersecting with clinical practice. As regulatory bodies and health institutions establish parameters to reduce opioid prescribing, continuous evaluation of these policies’ impacts on specific patient cohorts — like those with cancer — becomes essential. The data advocate for policies that maintain flexibility, enabling clinicians to exercise informed discretion grounded in comprehensive patient assessments.

In summary, this study delivers pivotal, evidence-based insights into opioid prescribing trends among adult cancer patients, illustrating a gradual but thoughtful reduction in opioid use aligned with patient-reported pain levels and clinical contexts. It confirms that reductions in opioid prescriptions are not uniform but instead reflect tailored clinical decision-making, a crucial consideration in minimizing harm while preserving compassionate cancer pain management.

The publication of these findings in CANCER journal, a peer-reviewed outlet of the American Cancer Society, furthers the discourse on optimizing cancer pain therapies in a multidimensional healthcare environment shaped by both public health imperatives and individualized patient needs. Future research will be critical to delineate best practices, integrate novel therapeutics, and balance patient safety with quality of life in cancer care.

Subject of Research: Trends in opioid prescribing and pain assessment among adult cancer patients

Article Title: Opioid prescribing trends and pain scores among adult patients with cancer in a large health system

News Publication Date: 22-Sep-2025

Web References:

• https://dx.doi.org/10.1002/cncr.70027
• https://acsjournals.onlinelibrary.wiley.com/journal/10970142

References:
Van Metre Baum L, Soulos PR, KC M, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Liberatore M, Leapman MS, Jairam V, Dinan MA, Gross CP, Park HS. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. CANCER. Published online September 22, 2025. doi:10.1002/cncr.70027

Keywords: Opioids, Cancer, Pain management, Opioid prescribing trends, Cancer-related pain, Metastatic cancer, Cancer surgery, Public health policy, Opioid epidemic, Clinical pharmacology, Pain assessment, Analgesic stewardship